CoreCap Advisors’s Alterity Therapeutics ATHE Stock Holding History

CoreCap Advisors’s Portfolio ATHE Stock Details ATHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$77	Hold	21	–	–	﹤0.01%	3071
2026 Q2	$113	Hold	21	–	–	﹤0.01%	3062
2026 Q1	$73	Hold	21	–	–	﹤0.01%	2862
2025 Q4	$65	Buy	+21	New	+$80	﹤0.01%	2892
2024 Q3	–	Sell	-21	Closed	-$38	–	2647
2024 Q2	$38	Hold	21	–	–	﹤0.01%	1561
2024 Q1	$43	Buy	+21	New	+$40	﹤0.01%	2479
2022 Q4	$75	Buy	+22	New	+$84	﹤0.01%	2324
2022 Q3	–	Sell	-22	Closed	–	–	640
2022 Q2	$0	Buy	+22	New	+$156	﹤0.01%	2124
2022 Q1	–	Sell	-22	Closed	-$1K	–	649
2021 Q4	$1K	Buy	+22	New	+$239	﹤0.01%	2044

Other funds holding ATHE

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Blue Trust Inc Alpharetta, Georgia $9.5B AUM 13.02% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

CoreCap Advisors's ATHE Position: Q3 2026 in Review

CoreCap Advisors held its Alterity Therapeutics (ATHE) position steady in Q3 2026 at 21 shares worth $77. The position accounts for ﹤0.01% of the portfolio, ranked #3071.

CoreCap Advisors first reported a position in ATHE in Q4 2021 and has held it in 9 quarters since. The position peaked at $1K in Q4 2021. 5 funds tracked by Wall St. Rank hold ATHE as of Q3 2026.

CoreCap Advisors held 21 shares of Alterity Therapeutics worth $77 as of Q3 2026.
CoreCap Advisors left its Alterity Therapeutics share count unchanged in Q3 2026.
Alterity Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #3071 holding.
CoreCap Advisors first reported a position in Alterity Therapeutics in Q4 2021 and has held it in 9 quarters since.
CoreCap Advisors's Alterity Therapeutics position peaked at $1K in Q4 2021.
5 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.